EXP Code Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: EXP Code Pharmaceutical Import Records from India — 4 Products, $137.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

EXP Code — Pharmaceutical Importer Profile (2026) | 4 Products, $137.5K Trade | TransData Nexus

EXP Code

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $137.5K Total Trade · DGFT Verified

EXP Code is a pharmaceutical importer based in Brazil with a total trade value of $137.5K across 4 products in 2 therapeutic categories. Based on 30 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. EXP Code sources from 2 verified Indian suppliers, with Vama Lifecare Private Limited accounting for 97.0% of imports.

EXP Code — Import Portfolio & Supplier Network

EXP Code import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to EXP Code?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vama Lifecare Private Limited	$1.1M	500	97.0%
Vama Health World Llp	$35.6K	12	3.0%

EXP Code sources from 2 verified Indian suppliers across 384 distinct formulations.

What Formulations Does EXP Code Import?

Formulation	Value	Ships
Harmless medicine for human consumption other details as per	$245.0K	65
Harmless medicine for human	$29.8K	13
Harmless medicine for human consumptionlevonorgestrel 20mcg batch no. tu03urj manufacturing date. apr-23 exp date.	$24.9K	1
Harmless medicine for human consumptionrotavirus vaccine batch no. x015553 manufacturing date. 03/2023 exp date.	$24.9K	1
Harmless medicine for human consumptioninj. thiotepa 15 MG batch no. lthpa1301 manufacturing date. may-23 exp date.	$24.0K	3
Harmless medicine for human consumptionbiphasic isophane insulin injection i.p100iu/ML 3ML batch no. nr7kr75 manufacturing	$23.0K	1
Harmless medicine for human consumptioninj. pembrolizumab 100 MG / 4 ML batch no. w034646 manufacturing date. aug-22	$22.7K	2
Harmless medicine for human consumptiondaratumumab concentrate for solution forinfusion 400 MG / 20 ML batch no.	$21.9K	1
Harmless medicine for human consumptioninj. vinblastine 10 MG batch no. i23h024a manufacturing date. aug-23 exp date.	$21.2K	2
Harmless medicine for human consumptioninj. octreotide 30 MG batch no. 370752 manufacturing date. 04/2023 exp date.	$18.8K	1
Harmless medicine for human consumptioninj. pembrolizumab 100 MG /4 ML batchno. w034646 manufacturing date. aug-22 exp	$17.1K	2
Harmless medicine for human consumptioninj. beractant 25 MG / ML 8 ML vialbatch no. 1202807 manufacturing date.	$17.1K	1
Harmless medicine for human consumptioninj. beractant 25 MG / ML 8 ML vial batch no. 1202807 manufacturing date. may-23	$16.9K	1
Harmless medicine for human consumptiontranexamic acid 500MG batch no. ac23004 manufacturing date. 09/2023 exp date.	$14.5K	1
Harmless medicine for human consumptionetanercept 50MG batch no. gr5514 manufacturing date. 04/2023 exp date.	$13.5K	1

EXP Code imports 384 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Daratumumab	Advanced Oncology	$69.0K	11	5.2%	4
2	Pembrolizumab	Advanced Oncology	$29.5K	4	1.5%	9
3	Vinblastine	Oncology	$28.9K	4	3.9%	2
4	Actinomycin	Advanced Oncology	$10.2K	11	0.3%	7

EXP Code imports 4 pharmaceutical products across 2 categories into Brazil totaling $137.5K.

EXP Code — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

EXP Code is a Brazilian pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Brazil, EXP Code plays a pivotal role in the country's pharmaceutical distribution network, ensuring the availability of essential medications to meet domestic healthcare needs. The company operates as a key intermediary between international manufacturers and the Brazilian market, facilitating the importation and distribution of a diverse range of pharmaceutical products.

As a dedicated pharmaceutical buyer, EXP Code focuses exclusively on sourcing finished formulations, thereby excluding raw active pharmaceutical ingredients (APIs) or bulk drugs from its procurement activities. This strategic approach allows the company to concentrate on delivering ready-to-use medications that adhere to Brazil's stringent regulatory standards. By maintaining a specialized portfolio, EXP Code effectively addresses the demand for high-quality pharmaceutical products within the Brazilian healthcare system.

2Distribution Network

EXP Code's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Brazil. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are tailored to meet the diverse needs of the Brazilian market. EXP Code's geographic coverage spans the entire country, enabling timely and reliable distribution to various regions, including urban centers and remote areas. This extensive reach ensures that essential medications are accessible to healthcare providers and patients nationwide.

The company's logistics operations are optimized to handle the complexities of pharmaceutical distribution, including compliance with Brazil's regulatory requirements and adherence to Good Distribution Practices (GDP). By leveraging a robust distribution network, EXP Code plays a crucial role in maintaining the integrity and availability of pharmaceutical products throughout Brazil.

3Industry Role

In Brazil's pharmaceutical supply chain, EXP Code functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from international suppliers, particularly from India, and facilitates their entry into the Brazilian market. By acting as an intermediary, EXP Code ensures that a diverse array of medications is available to meet the therapeutic needs of the Brazilian population.

While EXP Code does not engage in manufacturing or direct retail activities, its role as a distributor is vital. The company bridges the gap between global pharmaceutical manufacturers and the Brazilian healthcare system, ensuring that imported products comply with local regulations and are accessible to healthcare providers and patients. This intermediary function is essential for maintaining a steady supply of quality medications within Brazil.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — EXP Code

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

EXP Code's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from a single supplier: VAMA LIFECARE PRIVATE LIMITED. This supplier accounts for $1.1 million in imports, representing 97% of EXP Code's total import value. The remaining 3% is sourced from VAMA HEALTH WORLD LLP, amounting to $36,000.

This concentrated sourcing approach suggests a strategic partnership between EXP Code and VAMA LIFECARE PRIVATE LIMITED, potentially leading to favorable terms, consistent product quality, and reliable supply chains. However, such dependency also introduces risks associated with supplier disruptions, geopolitical factors, or changes in supplier policies. To mitigate these risks, it would be prudent for EXP Code to diversify its supplier base, ensuring a more resilient and adaptable supply chain.

The stability of the relationship between EXP Code and its primary supplier, VAMA LIFECARE PRIVATE LIMITED, is crucial. The substantial volume of imports from this supplier indicates a strong and ongoing partnership. Nonetheless, exploring additional suppliers could provide EXP Code with greater flexibility and security in its sourcing strategy.

2Supply Chain Resilience

EXP Code's supply chain resilience is closely tied to its sourcing practices, particularly the heavy reliance on a single supplier, VAMA LIFECARE PRIVATE LIMITED. This dependency could pose challenges in the event of supply disruptions, such as production delays, logistical issues, or regulatory changes affecting the supplier.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the National Health Regulatory Agency (ANVISA) is the primary authority overseeing the regulation of pharmaceutical products. ANVISA is responsible for ensuring that all pharmaceutical imports meet the country's health and safety standards. The agency's regulations encompass various aspects, including product registration, manufacturing practices, and post-marketing surveillance.

Key legislation governing pharmaceutical imports into Brazil includes Law No. 6,360/1976, which establishes the sanitary surveillance of medicines, drugs, pharmaceutical inputs, and related products. This law outlines the procedures and requirements for the importation of medicines, ensuring that imported products are safe, effective, and of high quality. Additionally, ANVISA's Resolution RDC 753/2022 provides specific guidelines for the registration of new synthetic and semi-synthetic drugs, as well as generic and similar drugs, detailing the necessary documentation and processes for market authorization. (gov.br)

2Import Licensing & GMP

Import licensing in Brazil requires importers to obtain authorization from ANVISA before bringing pharmaceutical products into the country. This process involves submitting detailed documentation, including proof of Good Manufacturing Practices (GMP) compliance, stability data, and labeling information. ANVISA assesses these submissions to ensure that imported products meet Brazil's health and safety standards. (gov.br)

EXP Code — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

EXP Code's focus on importing advanced oncology and oncology products aligns with the growing demand for cancer treatments in Brazil. The therapeutic areas of advanced oncology (79.0%) and oncology (21.0%) constitute the majority of the company's import portfolio. This strategic emphasis indicates a

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — EXP Code

What products does EXP Code import from India?

EXP Code imports 4 pharmaceutical products across 2 categories. Top imports: Daratumumab ($69.0K), Pembrolizumab ($29.5K), Vinblastine ($28.9K), Actinomycin ($10.2K).

Who supplies pharmaceuticals to EXP Code from India?

EXP Code sources from 2 verified Indian suppliers. The primary supplier is Vama Lifecare Private Limited (97.0% of imports, $1.1M).

What is EXP Code's total pharmaceutical import value?

EXP Code's total pharmaceutical import value from India is $137.5K, based on 30 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does EXP Code focus on?

EXP Code imports across 2 categories. The largest: Advanced Oncology (79.0%), Oncology (21.0%).

Get Full EXP Code Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.